Company Profile
Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Preventing healthcare-acquired infections is a growing concern in pre- and post-operative care. Mölnlycke is committed to human safety in all its actions and have made it a priority to reduce the risk of infections through effective hygiene measures and antibacterial skin protection. Mölnlycke’s innovative antiseptic products offer long-lasting antibacterial protection for the skin and ensure comprehensive protection against harmful pathogens, particularly when used prior to and after surgical procedures.
Approach to Healthcare
Mölnlycke’s Antiseptics Business Area has a vision of a world without healthcare acquired infections. Focusing on preoperative compliance and innovations, intraoperative synergistic infection prevention and post-operative body decolonisation. We apply our expertise to reduce the risk of infections at every stage of the patient journey.
Impact of Products/Services on Healthcare:
Mölnlycke’s Antiseptics Business Area offers innovative antiseptic products that provide long-lasting antibacterial protection for the skin and nose, particularly when used prior to and after surgical procedures. Antiseptics are committed to supporting customers enhance their natural protective barriers, by integrating antiseptic washing into infection control protocols.
The range of solutions includes products such as pre-operative nasal photo-disinfection, daily bathing antiseptics for inpatients, whole-body washing solutions for patients, and hand disinfectants for healthcare professionals, ensuring comprehensive protection against harmful pathogens.
All Mölnlycke Antiseptics’ product containers are made of recyclable plastic mono-materials, and all new product or process changes include sustainability considerations.
Innovation
Mölnlycke’s Antiseptics Business Area became the sole distributor of Steriwave in 2025. Steriwave is a revolutionary light-activated antimicrobial that destroys S. aureus and other nasal pathogens with a single, painless5-minute treatment. 1 in 3 patients carrying S.aureus in their nose, a leading cause of healthcare acquired infections. Steriwave’s photo-disinfection is typically administered up to 4 hours before surgery to ensure compliance to nasal decolonisation protocols; Steriwave offers a broad spectrum kill with no known antimicrobial resistance to this technology it offers benefits in the fight against AMR/AMS.
Future Direction
Mölnlycke is dedicated to providing high-quality products and solutions that meet the changing needs of the healthcare sector. The company focuses on developing solutions that are intuitive and easy to use, with a focus on patient safety, comfort, effectiveness and improved clinical outcomes.